Oct 30, 2018

Optimal strategies for inhibition of protein aggregation

BioRxiv : the Preprint Server for Biology
Thomas CT MichaelsL Mahadevan

Abstract

Protein aggregation has been implicated in many diseases. Therapeutic strategies for these diseases propose the use of drugs to inhibit specific molecular events during the aggregation process. However, viable treatment protocols require balancing the efficacy of the drug with its toxicity while accounting for the underlying events of aggregation and inhibition at the molecular level. Here, we combine aggregation kinetics and control theory to determine optimal protocols which prevent protein aggregation via specific reaction pathways. We find that the optimal inhibition of primary and fibril-dependent secondary nucleation require fundamentally different drug administration protocols. We test the efficacy of our approach on experimental data for Amyloid-beta aggregation of Alzheimer's disease in the model organism C. elegans. Our results pose and answer the question of the link between the molecular basis of protein aggregation and optimal strategies for inhibiting it, opening up new avenues for the design of rational therapies to control pathological protein aggregation.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Calcinus elegans
APBA3
Cyartonema elegans
Coleonyx elegans
Biochemical Pathway
Treatment Protocols
Cestrum elegans
Clarkia unguiculata
APP protein, human
Clathrulina elegans

About this Paper

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques. Here is the latest research.

Alzheimer's Disease: Genes&Microglia (Preprints)

Genes and microglia are associated with the risk of developing and the progression of conditions such as Alzheimer's Disease (AD). Here are the latest preprints pertaining to this disease.

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Alzheimer's Disease: Abeta

Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with accumulation of amyloid plaques, which are comprised of amyloid beta. Here is the latest research in this field.